Hepatocellular carcinoma after kidney transplantation: Analysis of Hong Kong Renal Registry

Renal Failure

Volumn 36, Issue 6, 2014, Pages 865-869

  Cheung, Chi Yuen ^a   Lam, Man Fai ^b   Chow, Kai Ming ^c   Lee, William ^d   Cheng, Yuk Lun ^e   Yuen, Sze Kit ^f   Wong, Ping Nam ^g   Mo, Ka Leung ^h   Leung, Kay Tai ⁱ   Wong, Sze Ho ^j   Ho, Yiu Wing ^j   Chau, Ka Foon ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d PRINCESS MARGARET HOSPITAL   (Hong Kong)

^e ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^f Caritas Medical Centre Hong Kong   (Hong Kong)

^g KWONG WAH HOSPITAL   (Hong Kong)

^h PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

ⁱ TUEN MUN HOSPITAL   (Hong Kong)

^j UNITED CHRISTIAN HOSPITAL   (Hong Kong)

more..

Author keywords

Hepatocellular carcinoma; Incidence; Kidney transplantation

Indexed keywords

ALPHA FETOPROTEIN;

ARTICLE; CANCER INCIDENCE; CANCER RISK; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HONG KONG; HUMAN; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; MALE; MIXED INFECTION; PRIORITY JOURNAL; ULTRASOUND; VIRUS CARRIER; ADULT; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; REGISTER; RETROSPECTIVE STUDY;

ADULT; CARCINOMA, HEPATOCELLULAR; FEMALE; HONG KONG; HUMANS; KIDNEY TRANSPLANTATION; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84903271675     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2014.899879     Document Type: Article

References (30)

1. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296: 2823-2831.
2. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004; 4:905-913.
3. Cheung CY, Lam MF, Chu KH, et al. Malignancies after kidney transplantation: Hong Kong renal registry. Am J Transplant. 2012; 12:3039-3046.
4. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61:1942-1956.
5. Fung KT, Fung J, Lai CL, Yuen MF. Etiologies of chronic liver diseases in Hong Kong. Eur J Gastroenterol Hepatol. 2007;19: 659-664.
6. Hong Kong Cancer Registry, Hospital Authority. Available at: www3.ha.org.hk/cancereg/. Accessed November 2013.
7. De Masi S, Tosti ME, Mele A. Screening for hepatocellular carcinoma. Dig Liver Dis. 2005;37:260-268.
8. Rugge JB, Lochner J, Judkins D. What is the best surveillance for hepatocellular carcinoma in chronic carriers of hepatitis B? J Fam Pract. 2006;55:155-156.
9. Penn I. Primary malignancies of the hepato-biliary-pancreatic system in organ allograft recipients. J Hepatobiliary Pancreat Surg. 1998;5:157-164.
10. Chiang YJ, Wang HH, Liu KL, Chu SH, Lee WC. Hepatocellular carcinoma following renal transplantation: experience in northern Taiwan. Transplant Proc. 2008;40:2397-2399.
11. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
12. Wong G, Chapman JR, Craig JC. Cancer screening in renal transplant recipients: what is the evidence? Clin J Am Soc Nephrol. 2008;3(Suppl. 2):S87-S100.
13. Yuen MF, Hou JL, Chutaputti A; Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009;24: 346-353.
14. Chuang CH, Chien YS, Cheng YT, et al. Hepatocellular carcinoma in renal transplant recipients. Transplant Proc. 2008;40:2392-2394.
15. He Y, Zhang H, Hin J, et al. IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. Carcinogenesis. 2009;30:1916-1922.
16. De Mitri MS, Cassini R, Morsica G, et al. Virological analysis, genotypes and mutational patterns of the HBV precore/core gene in HBV/HCV-related hepatocellular carcinoma. J Viral Hepat. 2006; 13:574-581.
17. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann NY Acad Sci. 2002;963:13-20.
18. Blackadar CB. Systematic review of hepatocellular carcinoma mortality rates among hepatitis B virus-infected renal transplant recipients, with supplemental analyses of liver failure and all-cause mortality. Int J Infect Dis. 2013;17:e24-e36.
19. Iloeje UH, Yang HI, Jen CL, et al. Risk evaluation of viral load elevation and associated liver disease/cancer-hepatitis B virus study group. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921-931.
20. Cheung TK, Lai CL, Wong BC, Fung J, Yuen MF. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther. 2006;24:573-583.
21. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
22. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29: 62-67.
23. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-422.
24. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
25. Manno M, Cammà C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology. 2004;127:756-763.
26. Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology. 2004;39:1694-1701.
27. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47.
28. Luo K, Liu Z, Karayiannis P. Effect of antiviral treatment on alfa-fetoprotein levels in HBV-related cirrhotic patients: early detection of hepatocellular carcinoma. J Viral Hepat. 2010;17: 511-517.
29. Han KH, Kim DY, Park JY, et al. Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months: a 15-year prospective study. J Clin Gastroenterol. 2013;47:538-544.
30. Singal AG, Yopp AS Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med. 2012; 27:861-867.